title: [Weekly administration of paclitaxel might be beneficial against TS-1-resistant recurrent gastric cancer--a case report].
abstract: At one year after postoperative adjuvant therapy consisting of TS-1, UFT, and PSK, lymph-node metastasis and recurrent suprarenal metastasis were confirmed in a patient with Stage IV gastric cancer. Despite TS-1 therapy (120 mg/body, 4 consecutive weeks, 2-week break), the therapeutic effect remained PR, and the severity of adverse reactions, such as skin symptoms, leukopenia, and diarrhea, ranged from grade 1 to 3. Although this therapy was continued intermittently, the therapeutic effect worsened to PD and, as a result, the therapy was discontinued. Next, in accordance with the treatment of recurrent and advanced breast cancer, weekly paclitaxel (PTX 80 mg/m2, 3 consecutive weeks, 1-week break) administration was performed on an outpatient basis. CR was achieved after 4 cycles. In addition, no adverse reactions were seen. Therefore, the weekly administration of PTX for the treatment of recurrent gastric cancer resistant to 5-FU anticancer agents is extremely useful, as the antitumor effect of this therapy was great, no adverse reactions were seen, and it can be performed on an outpatient basis.
authors.affiliation: Dept. of Surgery, Toyooka Hospital.
authors.forename: Michihiko
authors.initials: M
authors.lastname: Tsubono
authors.forename: Iwao
authors.initials: I
authors.lastname: Kaneko
authors.forename: Eiji
authors.initials: E
authors.lastname: Kii
authors.forename: Toshiro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Toru
authors.initials: T
authors.lastname: Murata
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Kamimura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kida
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000556:secondary*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005743:Gastrectomy; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D014057:Tomography, X-Ray Computed
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel